Tourmaline Bio (TRML) Expected to Announce Earnings on Thursday

Key Points

• Tourmaline Bio (NASDAQ:TRML) is set to announce its Q2 2025 earnings on Thursday, August 14th, with analysts predicting a loss of ($0.95) per share.
• The company's stock is currently priced at $21.94, with a 12-month low of $11.56 and a high of $29.79, reflecting a market cap of $563.42 million.
• Analysts have a consensus rating of "Buy" for Tourmaline Bio, with target prices ranging from $50.00 to $70.00 based on recent reports from HC Wainwright and Chardan Capital.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.95) per share for the quarter.

Tourmaline Bio Stock Performance

TRML traded down $0.61 during midday trading on Friday, hitting $20.72. The stock had a trading volume of 178,434 shares, compared to its average volume of 199,916. The company has a market cap of $532.09 million, a P/E ratio of -6.45 and a beta of 2.04. The business has a fifty day moving average of $18.71 and a 200 day moving average of $16.39. Tourmaline Bio has a 1 year low of $11.56 and a 1 year high of $29.79.

Institutional Trading of Tourmaline Bio

A hedge fund recently bought a new stake in Tourmaline Bio stock. Creative Planning acquired a new stake in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 12,592 shares of the company's stock, valued at approximately $201,000. Hedge funds and other institutional investors own 91.89% of the company's stock.

Analysts Set New Price Targets

TRML has been the subject of several research reports. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Tourmaline Bio in a research note on Monday, May 5th. Chardan Capital reiterated a "buy" rating and issued a $70.00 price objective on shares of Tourmaline Bio in a research report on Monday, May 5th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $49.33.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.